Get the Stockscreener App
7.44
2.49%
-0.19
Chromadex Corp stock is traded at $7.44, with a volume of 1.09M.
It is down -2.49% in the last 24 hours and up +113.18% over the past month.
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.
See More
Previous Close:
$7.63
Open:
$7.5
24h Volume:
1.09M
Relative Volume:
0.99
Market Cap:
$562.01M
Revenue:
$83.57M
Net Income/Loss:
$-4.94M
P/E Ratio:
-82.67
EPS:
-0.09
Net Cash Flow:
$6.97M
1W Performance:
+9.09%
1M Performance:
+113.18%
6M Performance:
+134.70%
1Y Performance:
+413.10%
1-Day Range:
$7.09
$7.52
1-Week Range:
$6.85
$7.85
52-Week Range:
$1.32
$7.85
Chromadex Corp Stock (CDXC) Company Profile
Name
Chromadex Corp
Sector
Industry
Phone
310-388-6706
Address
10900 WILSHIRE BLVD, LOS ANGELES
Compare CDXC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CDXC | 7.44 | 562.01M | 83.57M | -4.94M | 6.97M | -0.09 |
| KHC | 31.81 | 38.63B | 26.13B | 1.37B | 3.00B | 2.42 |
| GIS | 65.00 | 35.90B | 19.80B | 2.40B | 2.78B | 4.10 |
| K | 81.17 | 27.75B | 12.80B | 1.01B | 927.00M | 2.50 |
| MKC | 77.58 | 20.92B | 6.68B | 792.60M | 774.40M | 2.40 |
| HRL | 30.67 | 16.82B | 11.98B | 780.78M | 902.87M | 1.61 |
Chromadex Corp Stock (CDXC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-11-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Mar-08-22 | Initiated | ROTH Capital | Buy |
| Oct-16-19 | Initiated | Oppenheimer | Outperform |
| Feb-14-19 | Initiated | B. Riley FBR | Buy |
| Nov-27-17 | Resumed | H.C. Wainwright | Buy |
| Sep-25-17 | Initiated | Ladenburg Thalmann | Buy |
| Jan-03-17 | Initiated | Rodman & Renshaw | Buy |
View All
Chromadex Corp Stock (CDXC) Latest News
ChromaDex updates equity offering program, adds Roth Capital Partners - Investing.com
ChromaDex updates equity offering program, adds Roth Capital Partners By Investing.com - Investing.com UK
Recent Price Trend in ChromaDex (CDXC) is Your Friend, Here's Why - Yahoo Finance
ChromaDex Gears Up to Report Q3 Earnings: Here's What to Expect - MSN
ChromaDex stock soars to 52-week high, hits $7.58 By Investing.com - Investing.com Australia
ChromaDex stock soars to 52-week high, hits $7.58 - Investing.com
ChromaDex Co. (NASDAQ:CDXC) Short Interest Update - MarketBeat
ChromaDex Expands Niagen IV Access to 200+ Restore Hyper Wellness Clinics - Athletech News
, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement - Business Wire
ChromaDex (NASDAQ:CDXC) Sets New 12-Month HighHere's Why - MarketBeat
ChromaDex stock soars to 52-week high, hits $7.08 - Investing.com
ChromaDex (NASDAQ:CDXC) Cut to "Buy" at StockNews.com - MarketBeat
What Makes ChromaDex (CDXC) a Strong Momentum Stock: Buy Now? - Yahoo Finance
ChromaDex rolls out Niagen IV at wellness centers By Investing.com - Investing.com Australia
What is Roth Capital's Estimate for ChromaDex Q2 Earnings? - MarketBeat
ChromaDex rolls out Niagen IV at wellness centers - Investing.com India
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide - Business Wire
Research Analysts Issue Forecasts for ChromaDex Q4 Earnings - MarketBeat
Shareholders Can Be Confident That ChromaDex's (NASDAQ:CDXC) Earnings Are High Quality - Yahoo Finance
ChromaDex (NASDAQ:CDXC) Hits New 12-Month High After Analyst Upgrade - Defense World
HC Wainwright Issues Positive Outlook for ChromaDex Earnings - MarketBeat
ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
HC Wainwright Brokers Boost Earnings Estimates for ChromaDex - MarketBeat
ChromaDex records 31% sales growth; stock PT raised to $8 by H.C. Wainwright - Investing.com
Are Investors Keen On Selling Holdings In Chromadex Corp (NASDAQ: CDXC)? - Stocks Register
ChromaDex (NASDAQ:CDXC) Given New $8.00 Price Target at HC Wainwright - MarketBeat
BSW Wealth Partners Acquires Shares of 88,847 ChromaDex Co. (NASDAQ:CDXC) - MarketBeat
Roth Capital Estimates ChromaDex's Q2 Earnings (NASDAQ:CDXC) - MarketBeat
ChromaDex (NASDAQ:CDXC) Releases Quarterly Earnings Results - MarketBeat
ChromaDex Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
ChromaDex Corp (CDXC) Q3 2024 Earnings Call Highlights: Record R - GuruFocus.com
ChromaDex stock soars to 52-week high, hits $4.69 By Investing.com - Investing.com Nigeria
ChromaDex stock soars to 52-week high, hits $4.69 - Investing.com India
ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates - MSN
ChromaDex Corp (CDXC) Q3 2024 Earnings: EPS of $0.02 Beats Estimates, Revenue Hits $25.6 Million - GuruFocus.com
ChromaDex Corp (CDXC) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
ChromaDex surges on surprise Q3 profit - XM
ChromaDex: Q3 Earnings Snapshot - New Haven Register
ChromaDex Reports Strong Q3 2024 Financial Results - TipRanks
ChromaDex Corporation Reports Third Quarter 2024 Financial Results - BioSpace
ChromaDex Shares Climb on Forecast for 15% Revenue Growth - MarketWatch
Chromadex Reports Strong Q3 2024 with 31% Sales Increase - TipRanks
ChromaDex reports Q3 EPS 2c, consensus 0c - TipRanks
ChromaDex sees FY24 revenue growth 15% - TipRanks
ChromaDex Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Curious About NAD+? Here’s How It Works and How to Try It At Home - NewBeauty Magazine
ChromaDex Q3 2024 Earnings Preview - MSN
ChromaDex Corp (CDXC) Q3 2024 Earnings Report Preview: What To E - GuruFocus.com
Insights into ChromaDex's Upcoming EarningsChromaDex (NASDAQ:CDXC) - Benzinga
ChromaDex Co. (NASDAQ:CDXC) Sees Significant Drop in Short Interest - MarketBeat
Chromadex Corp Stock (CDXC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):